Microbiology and Immunology 2500A/B Lecture Notes - Lecture 29: Pneumocystis Jirovecii, Sanofi Pasteur, Aidsvax

• School: Western University
• Department: Microbiology and Immunology
• Course: Microbiology and Immunology 2500A/B
• Professor: David Colby

Document Summary

Hiv vaccines lecture 29 march 25th, 2019: dvlpt of prophylactic and therapeutic hiv vaccines. Lymphadenopathy: bump at back of neck behind ear, early sign of aids. Lung infection: pneumocystis carinii: most common infection in aids patients. 60-65% of patients with aids die from these infection: salmonells, shigella, camphylobacter, parasites, cryptosporidium, isospora, giardia, microsporidia, virus, cytomegalovirus. Prophylactic chemotherapy: gilead science"s truvada costs up to ,000 a year in the us, can prevent hiv infection by over 90% Hiv vaccine development: the most challenging problem in infectious diseases. 4 major human clinical trials of hiv/aids vaccines: vaxgen: aidsvax trial, 2003: rgp120, gp120 = surface glycoprotein. [51+/8,197 (0. 6%) vaccine group vs 74+/8,198 (0. 9%) placebo group] 31% efficacy: us niaid: hvtn 505 trial, 2013: dna & rad5, showed higher rate of infection in vaccinated group than control group, we have pre-existing antibodies against ad5. Currently ongoing hiv vaccine trials: note: no one uses the killed whole-hiv vaccine strategy.